Sustained Microdose Technology™
Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds: Psilocybin, MDMA, DMT, & LSD by the United States Drug Enforcement Agency (DEA).CONTACT US
- Pharma/Biotech company
- Developer of advanced drug delivery products
- Main focus psychedelic APIs and Mental Health
- Additional focus on ketamine treatment for cancer and cancer related conditions
- IP-protected Sustained Microdose Technology™ drives company’s core product line
- Mycrodose Therapeutics is building a robust patent portfolio protecting its pipeline of products under development.
- Comprehensive Transdermal delivery Patent for psychedelics
- Approved by the Attorney General in California, US Drug Enforcement Agency (DEA), and FDA for Research of Four (4) schedule I Psychedelics APIs: Psilocybin, MDMA, LSD, DMT.
- focused on 2 drug delivery systems to Treat multiple health indications
- Lab work and clinical supply production follow GLP and GMP regulations
Mycrodose Early Investors
- NEGEV CAPITAL
- The Conscious Fund
- K2 & Associates
- Private Investors
Advanced Drug Delivery Systems
The global market for advanced drug delivery systems will grow from $231 billion in 2020 to $310 billion by 2025. Mycrodose Therapeutics’ core business model and experience is in successfully developing these delivery systems for Psychedelic APIs to treat mental health
Mental Health Targets
The global market for mental health and cognitive diseases is currently a $120 billion market. Mycrodose Labs is in discovery phase on the following indications: Major Depressive Disorder, Anxiety, PTSD, Obesity, Substance Abuse, Postpartum, Alzheimer’s, Autism, Cognitive Degenerative Disease.
Functional Mushroom & Adaptogenic Compounds
The global market for functional mushrooms and adaptogens will rise from $25 billion in 2020 to over $37 billion by 2024. Reishi, Cordyceps, and Chaga are considered the top herbs in Traditional Chinese Medicine pharmacopoeia.
The company’s C-Suite has over 80 years of combined experience developing patented drug delivery technologies, a successful track-record of working with the FDA and navigating the clinic trial process, and a proven history of core business fundamentals and successful M&A ventures.
Chief Executive Officer
Chief Operating Officer
Frank Kochinke, PhD
Chief Science Officer
MENTAL HEALTH PANDEMIC IMPACTS OVER 1 BILLION LIVES
Mycrodose Therapeutics is dedicated to helping fight the mental health global pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe. It is our mission to develop cutting-edge technologies and novel IP in order to bring more happiness, love, connection, and understanding to those suffering.
Core Advanced Drug Delivery Technologies
Transdermal Delivery of Psilocybin (Transdermal Patch)
Our IP Protected transdermal technology delivers a sustained and controlled dose of medicine directly into the bloodstream, bypassing the liver, to reduce the potential of harmful toxicity, psychosis, and the common issues associated with standard macro dosing products.
Transmucosal Delivery of Ketamine (Lozenge)
Our IP Protected transmucosal lozenge technology also delivers a sustained and controlled dose of medicine into the body slowly over time. Our technology offers an advantage to other sublingual.
Mycrodose Therapeutics is expanding rapidly and has grown significantly since 2020. To receive the most updated Corporate Governance, Financial Statements, Investor Deck, or to reach the Executive Team please contact us below.
- Investor Deck
- Quarterly Updates
- Mycrodose Q&A
- Financials & Projections
- Board of Directors
- Advisory Team
- Media Correspondance
@2021 mycrodose therapeutics inc